Abstract
Esophageal cancer is a morbid disease with a grim prognosis. The outcomes of treatment even in non-metastatic disease undergoing potentially curative surgery are poor with 5-year survival ranging from 20 to 35 %. Several multimodality treatment options have been investigated in well-conducted randomised trials and meta-analyses evaluating both neoadjuvant and adjuvant therapies. However, there is still lack of uniform practice in the management of operable esophageal cancer. We review the current evidence for multimodality treatment of esophageal cancer, critically analysing the evidence supporting the use of each strategy, the pros and cons of each approach and discuss our approach in management. Neoadjuvant chemotherapy or chemoradiotherapy are currently the standard of care in localised esophageal cancer.
Similar content being viewed by others
References
Ferlay J, Soerjomataram I, Ervik M et al. (2012). GLOBOCAN, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr (Accessed on 22nd Dec 2013)
National Cancer Registry 2004. Available from http://www.icmr.nic.in/ncrp/first_report_2003-04/Chapter%20Final%20Pages%201%20to%2071.pdf (Accessed on 22nd Dec 2013)
Jha P, Gajalakshmi V, Gupta PC et al (2006) Prospective study of one million deaths in India: rationale, design, and validation results. PLoS Med 3:191–200
Kelsen DP, Winter KA, Gunderson LL et al (2009) Long-term results of RTOG trial 8911 (USA Intergroup113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 27:5062–5067
Allum WH, Stenning SP, Bancewicz J et al (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J ClinOncol 27:5062–5067
van Hagen P, Hulshof MC, van Lanschot JJ (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Boone J, Livestro DP, Elias SG et al (2009) International survey on esophageal cancer: part II staging and neoadjuvant therapy. Dis Esophagus 22:203–210
Geh JI, Crellin AM, Glynne-Jones R (2001) Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88:338–356
Hingorani M, Crosby T, Maraveyas A et al (2011) Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer—do we need another randomized trial? Clin Oncol 23:696–705
Arnott SJ, Duncan W, Gignoux M et al (1998) Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative group). Int J Radiat Oncol Biol Phys 41:579–583
Roth JA, Pass HI, Flanagan MM et al (1988) Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 96:242–248
Nygaard K, Hagen S, Hansen HS et al (1992) Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16:1104–1109
Schlag PM (1992) Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 127:1446–1450
Maipang T, Vasinanukorn P, Petpichetchian C et al (1994) Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 56:191–197
Law S, Fok M, Chow S et al (1997) Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114:210–217
Boonstra JJ, Kok TC, Wijnhoven BP et al (2011) Chemotherapy followed by surgery versus surgery alone in patients with oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 11:181
Ancona E, Ruol A, Santi S et al (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165–2174
Ychou M, Boige V, Pignon J-P et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721
Kelsen DP, Ginsberg R, Pajak T et al (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979–1984
Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359:1727–1733
Cunningham D, Allum WH, Stenning SP et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med; 355:11-20.
Urschel JD, Vasan H, Blewett CJ (2002) A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 183:274–279
Kaklamanos IG, Walker GR, Ferry K et al (2003) Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 10:754–761
Malthaner RA, Wong RKS, Rumble RB et al (2004) Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Medicine 2:35
Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226–234
Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692
Apinop C, Puttisak P, Preecha N (1994) A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology; 41:391–393
Le PE, Etienne PL, Meunier B et al (1994) A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73:1779–1784
Walsh T.(1995). The role of multimodality therapy in improving survival: a prospective randomised trial. In: Predicting, defining and improving outcomes for oesophageal carcinoma [MD thesis]. Dublin: Trinity College, University of Dublin: 124–50
Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462–467
Urba SG, Orringer MB, Turrisi A et al (2001) Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305–313
Lee JL, Park SI, Kim SB et al (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947–954
Burmeister BH, Smithers BM, Gebski V et al (2005) Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol 6:659–668
Tepper J, Krasna MJ, Niedzwiecki D et al (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086–1092
Mariette C, Seitz JF, Maillard E, et al. (2010). Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. Proc Am Soc Clin Oncol 2010; 28 (15 suppl)
Lv J, Cao XF, Zhu B et al (2010) Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol 16:1649–1654
van der Gaast A, van Hagen P, Hulshof M et al (2010) Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. Proc Am Soc Clin Oncol 28(15 suppl)
Bosset JF, Gignoux M, Triboulet JP et al (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337:161–167
Oppedijk V, van der Gaast A, van Lanschot JJ. (2014). Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. [Epub ahead of print]
Urschel JD, Vasan H. (2003). A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg; 185:538-43.
Fink U, Stein HJ, Wilke H (1995) Multimodal treatment for squamous cell esophageal cancer. World J Surg 19:198–204
Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856
Fok M, Sham JST, Choy D et al (1993) Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 113:138–147
Teniere P, Hay JM, Fingerhut A et al (1991) Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 173:123–130
Zieren HU, Muller JM, Jacobi CA et al (1995) Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 19:444–449
Xiao ZF, Yang ZY, Liang J et al (2003) Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg 75:331–336
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Ando N, Iizuka T, Ide H (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group study—JCOG9204. J Clin Oncol 21:4592–4596
Pouliquen X, Levard H, Hay JM et al (1996) 5-fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 223:127–133
Ando N, Iizuka T, Kakegawa T (1997) A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 114:205–209
Zhang J, Chen HQ, Zhang YW et al (2008) Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res 36:875–882
Ando N, Kato H, Igaki H (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74
Bhansali MS, Vaidya JS, Bhatt RG et al (1996) Chemotherapy for carcinoma of the esophagus: a comparison of evidence from meta-analyses of randomized trials and of historical control studies. Ann Oncol 7:335–355
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Purwar, P., Bambarkar, S., Jiwnani, S. et al. Multimodality Management of Esophageal Cancer. Indian J Surg 76, 494–503 (2014). https://doi.org/10.1007/s12262-014-1163-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-014-1163-x